First human tests begin for new eczema injection
NCT ID NCT06808477
Summary
This is an early-stage study to check the safety of a new drug called BBT001 for people with moderate-to-severe eczema (atopic dermatitis). Researchers will give the drug to healthy volunteers and eczema patients in increasing doses to see how well it is tolerated and how it moves through the body. The main goal is to find a safe dose and understand side effects before testing if it helps control the skin disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aotearoa Clinical Trials
RECRUITINGOtahuhu, Auckland, 2025, New Zealand
Contact
-
Equity Medical, LLC
NOT_YET_RECRUITINGThe Bronx, New York, 10455, United States
-
Linear Clinical Research
RECRUITINGPerth, Western Australia, 6009, Australia
Contact
-
Optimal Clinical Trials Central Auckland
RECRUITINGGrafton, Auckland, 1010, New Zealand
Contact
-
Optimal Clinical Trials Ltd - Christchurch
NOT_YET_RECRUITINGChristchurch Central City, Christchurch, New Zealand
-
Pacific Clinical Research Network (PCRN) - Auckland
RECRUITINGTakapuna, Auckland, 0622, New Zealand
Contact
-
Pacific Clinical Research Network (PCRN) Wellington
RECRUITINGUpper Hutt, 5018, New Zealand
Contact
Conditions
Explore the condition pages connected to this study.